FDA Form 3988 is a transmittal form that pharmaceutical and biologics companies must submit alongside postmarketing requirement (PMR) and postmarketing commitment (PMC) submissions to the FDA. Under Section 506B of the Federal Food, Drug, and Cosmetic Act, drug sponsors who fail to meet PMR milestones face civil monetary penalties up to $250,000 per violation—penalties that double every 30 days and can reach $10 million for all violations in a single proceeding.
As of 2022, 97% of the PMR/PMC backlog has been closed, but companies still manage thousands of open requirements each year. Errors in Form 3988 submissions can delay FDA review, trigger compliance issues, and jeopardize market access.
In this article, you will learn:
📋 Exactly when to use Form 3988 versus Form 3989 for your PMR/PMC submissions
⚠️ Field-by-field instructions with examples for every section of the form
💡 The three most common submission scenarios and how to handle each correctly
🚫 Critical mistakes that trigger FDA rejection and how to avoid them
✅ Do’s and Don’ts for staying compliant with postmarketing requirements
What Is FDA Form 3988?
FDA Form 3988 is titled “Transmittal of PMR/PMC Submissions for Drugs and Biological Products.” The form serves as a cover sheet that accompanies all postmarketing requirement and commitment-related submissions to the FDA—except for annual status reports.
The form applies to submissions for New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Biologics License Applications (BLAs), and Investigational New Drug (IND) applications. Think of Form 3988 as a routing slip that tells the FDA exactly what you are submitting, which PMR or PMC it addresses, and how to process your submission correctly.
Who Must Use This Form?
Form 3988 is designed for “applicants”—the legal entities holding approved NDAs, ANDAs, or BLAs. For NDAs and ANDAs, the applicant is any person who submits or owns an approved application under 21 CFR 314.3. For BLAs, the applicant is the person or legal entity to which the license has been issued.
| Applicant Type | Governing Regulation | Definition |
|---|---|---|
| NDA Holder | 21 CFR 314.3 | Person who submits/owns approved NDA, including 505(b)(2) applications |
| ANDA Holder | 21 CFR 314.3 | Person who submits/owns approved ANDA |
| BLA Holder | 21 CFR 601.2(a) | Person or legal entity to which the license has been issued |
PMRs vs. PMCs: Understanding the Difference
Before filling out Form 3988, you need to understand the distinction between PMRs and PMCs, as the form applies to both.
Postmarketing Requirements (PMRs) are studies or clinical trials that sponsors are required to conduct under statute or regulation. The FDA can require PMRs under several authorities, including Section 505(o)(3) of the FD&C Act for safety studies, the Pediatric Research Equity Act (PREA), accelerated approval regulations, and the animal efficacy rule.
Postmarketing Commitments (PMCs) are studies or clinical trials that a sponsor has agreed in writing to conduct, but that are not legally required. PMCs are often negotiated during the drug approval process to address questions about long-term safety or effectiveness.
| Feature | PMR | PMC |
|---|---|---|
| Legal Basis | Required by statute/regulation | Agreed upon in writing |
| Enforcement | Civil monetary penalties possible | No monetary penalties |
| Examples | 505(o)(3) safety studies, PREA pediatric studies | Long-term observational studies |
| FDA Authority | Can mandate changes | Relies on sponsor cooperation |
When to Use Form 3988 vs. Form 3989
The FDA created two forms for postmarketing study management. Understanding which form to use prevents routing errors and processing delays.
Use Form 3988 for:
- Draft protocol submissions
- Final protocol submissions
- Interim reports
- Final reports
- General correspondence about PMRs/PMCs
- PREA deferral extension requests
- Responses to FDA information requests
- Requests for revised milestones
- Requests for release from a PMR/PMC
Use Form 3989 for:
- Annual Status Reports (ASRs) on open PMRs and PMCs
Do not use Form 3988 for annual status reports—that is what Form 3989 is designed for. The FDA specifically states in the form instructions that Form 3988 “is not intended to accompany an Annual Status Report (ASR) submission.”
Field-by-Field Instructions for Form 3988
The following instructions correspond to the numbered boxes on Form FDA 3988. Each field must be completed accurately to ensure proper processing.
Field 1: Center
Check only one box indicating which FDA Center approved or licensed your application. CDER (Center for Drug Evaluation and Research) handles most drug applications. CBER (Center for Biologics Evaluation and Research) handles biological products.
Example: If your product is a small-molecule prescription drug approved under an NDA, check the CDER box. If your product is a therapeutic vaccine approved under a BLA, check the CBER box.
Field 2: Date of Submission
Enter the date you are submitting the form to the FDA. Use the mm/dd/yyyy format. The date should match the date on your cover letter.
Example: If you are submitting on March 15, 2026, enter “03/15/2026.”
Field 3: Applicant Name
Enter the name of the applicant exactly as it appears on your approved application. This is the legal entity holding the NDA, ANDA, or BLA.
Example: “Bristol-Myers Squibb Company” or “Pfizer Inc.”
Field 4: Application Type
Select only one application type by checking the appropriate box:
- NDA (New Drug Application)
- BLA (Biologics License Application)
- ANDA (Abbreviated New Drug Application)
- IND (Investigational New Drug)
Field 5: Application Number
Provide the six-digit application number. If your application number has fewer than six digits, add leading zeros.
Example: Instead of “12345,” enter “012345.” For BLAs, enter the six-digit Submission Tracking Number (STN).
Field 6: Supplement Number(s)
This field applies if your PMR/PMC was established in a supplemental application. Provide the four-digit supplement number, adding leading zeros if necessary. Separate multiple supplement numbers with commas.
| Application Type | Format | Example |
|---|---|---|
| CDER NDA/ANDA/BLA | Four digits with leading zeros | 0001, 0015 |
| CBER Applications | Four-digit Secondary STN | 5463 |
Field 7: Established Name
Provide the established name of the approved drug product. Use the United States Pharmacopeia (USP) or United States Adopted Name (USAN). For biological products, use the proper name.
Example: “acetaminophen” (not “Tylenol”) or “adalimumab” (not “Humira”)
Field 8: Proprietary Name(s)
Provide the trade name(s) of your product, if any.
Example: “Humira” or “Keytruda”
Section 9: PMR/PMC Information
This is the most detailed section of the form. Complete it for every PMR or PMC addressed in your submission. If you are addressing more than three PMRs/PMCs, click the “Add Row” button to add fields for additional requirements.
Type: Select either PMR or PMC from the drop-down menu.
PMR or PMC Number: Use the Center-specific format:
- CDER: Use XXXX-XX format (e.g., “1234-10”)
- CBER: Use “STN XXXXX/XXXX PMR/PMC #” format (e.g., “STN 12345/5463 PMC 1”)
Establishment Date: Enter the date from the letter that first communicated the final PMR or PMC—usually an approval letter or a post-approval acknowledgment letter. Use mm/dd/yyyy format.
National Clinical Trial (NCT) Number: Enter the ClinicalTrials.gov registration number if applicable. Use the format “NCT XXXXXXX.”
Field 10: PMR/PMC Submission Type
Check all document types you are including with this submission. Options include:
| Submission Type | Description |
|---|---|
| Draft Protocol | Initial version of study/trial protocol |
| Final Protocol | FDA-concurred version of protocol |
| Interim Report | Progress reports during study conduct |
| Final Report | Summary report intended to complete the PMR/PMC |
| General Correspondence | Questions, updates, or other PMR/PMC communications |
| PREA PMR Deferral Extension Request | Request to extend pediatric study deadlines |
| Response to Information Request | Reply to FDA’s request for additional information |
| Request for Revised Milestones | Proposal to change agreed-upon milestone dates |
| Request for Release of PMR/PMC | Formal request to be released from the obligation |
| Other | PMR/PMC-related submissions not covered above |
Important Note for Protocols: Submit clinical protocols to your IND with a cross-reference letter to the marketing application. Submit nonclinical and chemistry, manufacturing, and controls (CMC) protocols directly to the NDA, ANDA, or BLA.
Field 11: Description of Submission Content
Provide a brief explanation of what you are submitting and why. Be specific and reference the PMR/PMC number.
Good Examples:
- “To provide the final protocol for PMR 1234-10 incorporating information from our recent communications with FDA”
- “To provide the final report to fulfill PMR 2345-11”
- “General correspondence requesting a release from PMC 3456-12 because the study is no longer feasible”
Fields 12-16: Responsible Official Information
Field 12.a.: Enter the name and title of the person responsible for certifying compliance. This can be the applicant or an authorized U.S. agent.
Field 12.b.: Enter the date of signature using mm/dd/yyyy format.
Fields 13-15: Provide the telephone number, fax number, and email address for the Responsible Official.
Field 16: Provide the complete mailing address for the Responsible Official.
Fields 17: Signatures
Field 17.a.: The form must be signed by the applicant, or the applicant’s attorney, agent, or other authorized official.
Field 17.b.: If the signer in Field 17.a. does not reside or have a place of business in the United States, this field must be countersigned by an attorney, agent, or other authorized official who does reside or maintain a U.S. place of business.
Three Common Scenarios
Scenario 1: Submitting a Final Protocol
Situation: Sarah is a regulatory affairs manager at a pharmaceutical company. The FDA required a postmarketing clinical trial under Section 505(o)(3) when her company’s diabetes drug was approved. She is now submitting the final protocol for FDA review.
| Action | Consequence |
|---|---|
| Complete Fields 1-9 with application and PMR information | FDA can identify the correct product and requirement |
| Check “Final Protocol” in Field 10 | FDA routes to the appropriate review division |
| Write in Field 11: “To provide the final protocol for PMR 1234-10 for the required cardiovascular outcomes trial” | Reviewers understand the purpose of submission |
| Submit to IND with cross-reference letter to NDA | Meets regulatory requirements for clinical protocol submission |
| Obtain signature from Responsible Official | Certifies compliance with applicable laws |
Scenario 2: Requesting a Milestone Revision
Situation: Michael’s company is conducting a PREA-required pediatric study but enrollment is slower than expected due to the rare disease population. He needs to request revised milestone dates.
| Action | Consequence |
|---|---|
| Check “Request for Revised Milestones” in Field 10 | FDA understands this is a timeline change request |
| Add heading to cover letter: “Notification of Anticipated Failure to Meet a PMR Milestone(s) Required Under Section 505(o)” | Meets specific labeling requirements for 505(o)(3) PMRs |
| Provide detailed justification in Field 11 | FDA can evaluate whether “good cause” exists |
| Include proposed new milestone dates | FDA can assess feasibility of revised timeline |
Scenario 3: Submitting a Final Report
Situation: Jennifer’s company has completed a required postmarketing safety study and is submitting the final report to fulfill the PMR.
| Action | Consequence |
|---|---|
| Check “Final Report” in Field 10 | FDA knows to review for PMR fulfillment |
| Include complete study data and analysis | FDA can determine if PMR is fulfilled |
| Write in Field 11: “To provide the final report to fulfill PMR 2345-11” | Clear statement of intent |
| Label submission: “Required Postmarketing Final Report Under 505(o)” | Meets labeling requirements from approval letter |
Mistakes to Avoid
Mistake #1: Using Form 3988 for Annual Status Reports
The consequence is that FDA will return your submission or experience processing delays. Annual status reports must use Form 3989.
Mistake #2: Incorrect Date Format
The consequence is validation errors and potential rejection. Always use mm/dd/yyyy format (e.g., 03/15/2026, not March 15, 2026).
Mistake #3: Wrong PMR/PMC Number Format
The consequence is that FDA cannot match your submission to the correct requirement. CDER uses XXXX-XX format; CBER uses STN XXXXX/XXXX format.
Mistake #4: Submitting Clinical Protocols to the Wrong Application
The consequence is improper submission routing and review delays. Clinical protocols requiring an IND must be submitted to the IND with a cross-reference letter to the marketing application.
Mistake #5: Missing Countersignature for Non-U.S. Applicants
The consequence is an incomplete submission. If the signer does not reside or have a U.S. place of business, a U.S.-based authorized official must countersign.
Mistake #6: Vague Description in Field 11
The consequence is delays while FDA seeks clarification. Be specific: reference the PMR/PMC number and clearly state the purpose.
Mistake #7: Forgetting to Include NCT Number
The consequence is non-compliance with ClinicalTrials.gov requirements. For 505(o)(3) clinical trials, include the NCT number or submit Form FDA 3674.
Do’s and Don’ts
Do’s
✅ Do verify your application number has six digits. Add leading zeros if necessary to avoid rejection.
✅ Do check the PMR/PMC public database. Confirm your PMR/PMC number and status at the FDA’s searchable database before submitting.
✅ Do submit electronically. The FDA strongly encourages electronic submission through the eCTD format for efficiency.
✅ Do use the “Add Row” button for multiple PMRs/PMCs. Complete all fields for each requirement addressed in your submission.
✅ Do match the establishment date to your approval or acknowledgment letter. This date is critical for FDA tracking.
Don’ts
❌ Don’t include Form 3988 with cross-reference letters. The form accompanies the protocol submission itself, not the cross-reference.
❌ Don’t submit both Form 3988 and Form 3989 together. They serve different purposes and should not be combined.
❌ Don’t use this form for CMC commitments. Chemistry, manufacturing, and controls commitments not subject to Section 506B reporting are handled separately.
❌ Don’t forget to sign electronically. The form supports electronic signatures—click the “Sign” button after completing all required fields.
❌ Don’t include confidential commercial information in Field 11. The explanation of status may be displayed on FDA’s public PMR/PMC database.
How to Submit Form 3988
Form 3988 must be submitted electronically as part of your eCTD (electronic Common Technical Document) submission. Include the form in section 1.1 (Forms) of the eCTD. If your eCTD publishing tool does not have a place for Form 3988 under section 1.1, submit it in section 1.2 (Cover Letter).
The form is fillable and supports electronic signatures. After completing all mandatory fields, click the “Sign” button to access the electronic signature fields.
PMR/PMC Milestone Status Categories
When completing Form 3988, understand how the FDA categorizes study status:
| Status | Definition | Displayed Publicly? |
|---|---|---|
| Pending | Study not initiated; original start date has not passed | No |
| Ongoing | Study proceeding on or ahead of schedule | No |
| Delayed | Study behind original schedule | Yes |
| Submitted | Final report submitted; awaiting FDA determination | No |
| Terminated | Study ended before completion; no final report submitted | Yes |
| Fulfilled | FDA confirmed PMR/PMC requirements met | N/A (closed) |
| Released | FDA released sponsor from obligation | N/A (closed) |
FAQs
Is FDA Form 3988 required for all postmarketing submissions?
No. Form 3988 is optional but strongly encouraged by the FDA. It provides standardized information that helps expedite routing and review of your submission.
Can I use Form 3988 for my annual status report?
No. Annual status reports must use Form FDA 3989. Form 3988 is specifically designed for other PMR/PMC submissions like protocols, interim reports, and final reports.
Does Form 3988 replace Form FDA 356h?
No. You are still required to submit Form FDA 356h with submissions to your original and supplemental NDA, ANDA, and BLA as applicable.
What happens if I miss a PMR milestone?
Noncompliance with 505(o)(3) milestones can result in civil monetary penalties of up to $250,000 per violation, doubling every 30 days, unless you demonstrate good cause.
How do I know my PMR/PMC number?
Check your FDA approval letter or acknowledgment letter. The PMR/PMC number is first communicated in the letter that established the requirement.
Can I request to be released from a PMR?
Yes. Check “Request for Release of PMR/PMC” in Field 10 and provide justification in Field 11. The FDA may release you if the study is no longer feasible or would no longer provide useful information.
What format should I use for the NCT number?
Use “NCT” followed by eight digits (e.g., NCT12345678). If you have multiple NCT numbers for one PMR/PMC, indicate that a list is attached.
Does Form 3988 apply to generic drugs?
Yes. Form 3988 applies to ANDAs (Abbreviated New Drug Applications) for generic drugs when PMRs or PMCs have been established.
Where do I submit Form 3988?
Include it in section 1.1 (Forms) of your eCTD submission. If your software does not support that location, submit it in section 1.2 (Cover Letter).
What if my company is based outside the United States?
A U.S.-based authorized official must countersign the form in Field 17.b. if the primary signer in Field 17.a. does not reside or have a place of business within the U.S.